完整後設資料紀錄
DC 欄位語言
dc.contributor.authorLee, Chih-Hsienen_US
dc.contributor.authorWei, Jengen_US
dc.date.accessioned2017-04-21T06:55:27Z-
dc.date.available2017-04-21T06:55:27Z-
dc.date.issued2016-07-08en_US
dc.identifier.issn1995-1892en_US
dc.identifier.urihttp://dx.doi.org/10.5830/CVJA-2016-034en_US
dc.identifier.urihttp://hdl.handle.net/11536/132932-
dc.description.abstractThe prevalence of end-stage heart failure (HF) is on the increase, however, the availability of donor hearts remains limited. Left ventricular assist devices (LVADs) are increasingly being used for treating patients with end-stage HF. LVADs are not only used as a bridge to transplantation but also as a destination therapy. HeartMate II, a new-generation, continuous-flow LVAD (cf-LVAD), is currently an established treatment option for patients with HF. Technological progress and increasing implantation of cf-LVADs have significantly improved survival in patients with end-stage HF. Here we report a case of a patient with end-stage HF who was successfully supported using cf-LVAD implantation with adjuvant tricuspid valve repair in a general district hospital.en_US
dc.language.isoen_USen_US
dc.subjectcf-LVADen_US
dc.subjectend-stage heart failureen_US
dc.subjectHeartMate IIen_US
dc.titleSuccessful continuous-flow left ventricular assist device implantation with adjuvant tricuspid valve repair for advanced heart failureen_US
dc.identifier.doi10.5830/CVJA-2016-034en_US
dc.identifier.journalCARDIOVASCULAR JOURNAL OF AFRICAen_US
dc.citation.volume27en_US
dc.citation.issue4en_US
dc.citation.spageE14en_US
dc.citation.epageE16en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000384800700005en_US
顯示於類別:期刊論文